Harnessing pyrimidine as a building block for histone deacetylase inhibitors
- 18 July 2023
- journal article
- review article
- Published by Wiley in Archiv der Pharmazie
- Vol. 356 (10) , e2300208
Abstract
Histone deacetylase (HDAC) inhibitors are well‐established multifaceted bioactive agents against tumors and neurodegenerative disorders. Pyrimidine and its fused and substituted derivatives were employed as a surface recognition moiety of HDAC inhibitors. De facto, the literature was loaded with different success stories of pyrimidine‐based HDAC inhibitors that garnered much interest. Provoked by our continuous interest in HDAC inhibitors, we summarized and elaborated on the successful harnessing of the pyrimidine scaffold in this regard. Furthermore, we dissect our perspective that may guide medicinal chemists for an effective future design of more active chemotherapeutic agents with potential clinical applications.Keywords
This publication has 71 references indexed in Scilit:
- 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase InhibitorJournal of Medicinal Chemistry, 2010
- JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral ActivityClinical Cancer Research, 2009
- Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic CarcinomaPancreas, 2008
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomyBritish Journal of Cancer, 2008
- R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignanciesBritish Journal of Cancer, 2007
- Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular CarcinomaOncology, 2007
- Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitorsBioorganic & Medicinal Chemistry Letters, 2007
- Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinomaLung Cancer, 2005
- Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitorsEuropean Journal of Medicinal Chemistry, 2005